Acer Therapeutics' hot flashes drug fails mid-stage study goal
17/03/2023 12:40
March 17 (Reuters) - Acer Therapeutics Inc ACER.O said on Friday its
experimental drug to treat menopausal symptoms failed to reduce the frequency or
severity of hot flashes in postmenopausal women.
The company's shares fell nearly 30% premarket after it said it is pausing
the trial to review the trial data.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shailesh Kuber)
((Mariam.ESunny@thomsonreuters.com;))
Recent news on Acer Therapeutics
See all newsBrief: Leading Independent Proxy Advisory Firms Iss And Glass Lewis Recommend Acer Therapeutics Shareholders Vote "For" The Proposed Merger And Related Proposals
U.S. STOCKS ON THE MOVE-UGI, SkyWest, Sage Therapeutics
Acer Therapeutics surges on Zevra buyout deal
Brief: Zevra Therapeutics To Acquire Acer Therapeutics, Expanding Its Rare Disease Portfolio And Adding Commercial Product
Swiss stocks - Factors to watch on August 31